Cellivery Therapeutics, Inc.
268600.KQFinancial Statements
Income Statement (Annual)
Amounts in millions
2023
12/31/2023
Revenue
14
Cost of Revenue
14
Gross Profit
-0
Gross Margin
-1.8%
Operating Income
-15
Operating Margin
-103.7%
Net Income
-24
Net Margin
-172.7%
EPS (Basic)
$-1.00
EPS (Diluted)
$-1.00
EBITDA
-18
EBITDA Margin
-126.5%
2022
12/31/2022
Revenue
17
Cost of Revenue
20
Gross Profit
-2
Gross Margin
-12.6%
Operating Income
-51
Operating Margin
-291.3%
Net Income
-56
Net Margin
-324.5%
EPS (Basic)
$-2.00
EPS (Diluted)
$-2.00
EBITDA
-48
EBITDA Margin
-273.5%
2021
12/31/2021
Revenue
3
Cost of Revenue
3
Gross Profit
0
Gross Margin
0.6%
Operating Income
-21
Operating Margin
-724.4%
Net Income
-21
Net Margin
-724.8%
EPS (Basic)
$-1.00
EPS (Diluted)
$-1.00
EBITDA
-19
EBITDA Margin
-660.1%
2020
12/31/2020
Revenue
1
Cost of Revenue
1
Gross Profit
-1
Gross Margin
-162.5%
Operating Income
-13
Operating Margin
-2360.4%
Net Income
-13
Net Margin
-2264.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-12
EBITDA Margin
-2114.0%
2019
12/31/2019
Revenue
2
Cost of Revenue
3
Gross Profit
-1
Gross Margin
-71.2%
Operating Income
-11
Operating Margin
-703.3%
Net Income
-15
Net Margin
-947.6%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-14
EBITDA Margin
-895.6%